compared with pioglitazone, use of rosiglitazone was associated with a statistically significant increase in the odds of myocardial infarction (n=15 studies; odds ratio 1.16, 95% confidence interval 1.07 to 1.24; p<0.001; i2=46%), congestive heart failure (n=8; 1.22, 1.14 to 1.31; p<0.001; i2=37%), and death (n=8; 1.14, 1.09 to 1.20; p<0.001; i2=0%).